Novo Nordisk(US:NVO) Globenewswire·2025-09-25 17:41Core Viewpoint - Novo Nordisk A/S is facing a class action lawsuit due to a significant reduction in its fiscal year 2025 guidance, which has led to a substantial drop in its stock price and alleged misleading statements made by the company during the class period [2][3][4]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk revised its fiscal year 2025 guidance, lowering sales growth expectations from 13-21% to 8-14% and operating profit from 16-24% to 10-16% [2]. - The company cited lower growth expectations for its products Ozempic and Wegovy, attributing this to market expansion slowdowns, increased competition, and ongoing use of compounded GLP-1s [2]. Group 2: Stock Impact - Following the announcement of the revised guidance, Novo Nordisk's stock price fell by $15.06, or 21.8%, closing at $53.94 per share on July 29, 2025 [3]. Group 3: Legal Action - The class action lawsuit alleges that during the class period, Novo Nordisk made materially false and misleading statements and failed to disclose adverse facts about its business and prospects [4]. - Specific allegations include the company's failure to recognize the significance of the personalization exception for GLP-1 compounding and overestimating its ability to attract patients transitioning from compounded treatments [4]. - Investors who purchased Novo Nordisk securities during the class period have until September 30, 2025, to file a lead plaintiff motion in the lawsuit [5].